News

FAMPYRA is a prolonged-release (sustained release) tablet formulation of the drug fampridine (4-aminopyridine, 4-AP or dalfampridine). The CHMP recommended the conditional marketing authorisation of FAMPYRA to improve walking

Vectura‘s net income operating income was £13.3m, compared to £15.3m for the same period in 2010. The company’s gross profit increased by 10% to £40.2m (2009/10: £36.6m). Vectura

Based on a field alert report for packaging and labeling compliance for unit III, the FDA has asked the company for submitting a detailed action plan on rectifying

PRS-080 demonstrated Anticalins’ ability to encapsulate small targets like hepcidin with specificity and potency. In the trial, PRS-080 displayed sub-nanomolar potency, which translated into cell-based and in-vivo efficacy.

Edurant, a non-nucleoside reverse transcriptase inhibitor (NNRTI), is used as part of a highly active antiretroviral therapy (HAART) regimen that is designed to suppress the amount of HIV

China Ruitai’s net income was $735,893, or $0.03 per diluted share, compared to net income of $1.94m, or $0.07 per diluted share, for the comparable period last year.

NorLevo is to be taken within 72 hours following an unprotected sexual intercourse. Laboratoire HRA Pharma has licensed the development and commercialization rights for NorLevo Tablets to Sosei

Inspra (eplerenone) is a steroid nucleus-based mineralcorticoid receptor (MR) antagonist with a higher degree of selectivity than spironolactone. In the Phase 3B, multinational, randomized, double-blind placebo-controlled, parallel-group trial,

The CHMP has recommended to grant the marketing authorization for Vibativ (telavancin hydrochloride) as a treatment for adults who are suffering from nosocomial pneumonia with ventilator-associated pneumonia, known